

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): MARCIREAU ET AL. EXAMINER : M. MONSHIPOURI
SERIAL NO. : 09/744,125 ART UNIT : 1652
FILED : SEPTEMBER 17, 2001
FOR : MEKK1-INTERACTING FHA PROTEIN

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on Jan 3, 2003

Debra Coughlin
(Signature and Date)

RESPONSE TO REQUIREMENT FOR RESTRICTION
UNDER 35 U.S.C. § 121

ASSISTANT COMMISSIONER OF PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

In response to the Office Action dated December 3, 2002 in connection with the above-identified Application and in accordance with Rules 111 and 142(a) of the Rules of Practice, please consider the following remarks.

1652

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
MARCIREAU et al.Examiner: **M. Monshipour**Application No.: **09/744,125**


Art Unit:

1652

Filed: **September 17, 2001**Title: **MEKKI-INTERACTING FHA
PROTEIN**I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

Date of Deposit

Signature

Commissioner for Patents
Washington, D.C. 20231
Sir:

Transmitted herewith is an amendment in the above-identified application.

☒ No additional fee is required.

The fee has been calculated as shown below.

(1)	(2) CLAIMS REMAINING AFTER AMENDMENT*	(3)	(4) HIGHEST NUMBER PREVIOUSLY PAID FOR** / ***	(5) PRESENT EXTRA	(6) RATE	(7) ADDITIONAL FEE
TOTAL CLAIMS	27	MINUS	44	0	18.00	0.00
INDEPENDENT CLAIMS	2	MINUS	5	0	84.00	0.00
MULTI-DEPENDENT CLAIMS(S), Per Application (280.00)						
TOTAL AMENDMENT FEE FOR THIS AMENDMENT						0

* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

** If the "Highest Number Previously Paid For" in Total Claims is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" in (Independent Claims) is less than 3, write "3" in this space.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be
required by this paper or credit any overpayment to Account No. 18-1982. Two duplicate copies of
this paper are enclosed.

Respectfully submitted,

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant
Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. A3233A US